Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinlarebant study in adolescents with Stargardt disease type 1
ACTRN12621000549820Phase 2Completed
- Sponsor
- RBP4
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of tinlarebant in ABCA4-related Stargardt disease (STGD1) (2 arms), sponsored by RBP4. Primary endpoints: Systemic safety and tolerability, Optimal dose determination and 1 more. Started Mar 2021; status: completed.
02
Drugs
tinlarebant
03
Conditions
ABCA4-related Stargardt disease (STGD1)
Beyond the preview
Go deeper on ACTRN12621000549820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000549820.